Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable stage IIIA-bulky N2 and stage IIIB nonsmall cell lung carcinoma: An Italian lung cancer project observational study

Cancer

Volumn 98, Issue 1, 2003, Pages 128-134

  Cappuzzo, Federico ^a   Selvaggi, Giovanni ^b   Gregorc, Vanesa ^c   Mazzoni, Francesca ^a   Betti, Maura ^c   Migliorino, Maria Rita ^d   Novello, Silvia ^b   Maestri, Antonio ^a   De Marinis, Filippo ^d   Darwish, Samir ^c   De Angelis, Verena ^c   Nelli, Fabrizio ^d   Bartolini, Stefania ^a   Scagliotti, Giorgio V ^b   Tonato, Maurizio ^c   Crinò, Lucio ^a  

^a BELLARIA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Monteluce Hospital   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Chemotherapy; Cisplatin; Gemcitabine; Nonsmall cell lung carcinoma (NSCLC)

Indexed keywords

CISPLATIN; GEMCITABINE; HEMOGLOBIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW TOXICITY; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE COURSE; DOSE RESPONSE; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HEMOGLOBIN DETERMINATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THORACOTOMY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0038002649     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11460     Document Type: Article

References (28)

1. Lilenbaum RC, Green M. Multimodality therapy for nonsmall cell lung cancer. Oncology. 1994;8:25-31.
2. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer: adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol. 1997;15:2996-3018.
3. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899-909.
4. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in Stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer. 1995;76:593-601.
5. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med. 1996;125:723-79.
6. Rosell R, Lopez-Cabrerizo MP, Astudillo J. Preoperative chemotherapy for Stage IIIA non-small cell lung cancer. Curr Opin Oncol. 1996;9:149-155.
7. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med. 1994;330:153-158.
8. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable Stage IIIA non-small cell lung cancer. J Natl Cancer Inst. 1994;86:673-680.
9. Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg. 1992;53:992-998.
10. Mountain CF. Revision of the international system for staging lung cancer. Chest. 1997;111:1710-1717.
11. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable Stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002;20:247-253.
12. Crinò L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: a Phase II study. J Clin Oncol. 1997;15:297-303.
13. Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol. 1997;15:744-749.
14. Sandler A, Nemunaitis J, Dehnam C, et al. Phase III trial on gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non small cell lung cancer. J Clin Oncol. 2000;18:122-130.
15. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized Phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol. 1999;17:12-18.
16. Crinò; L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized Phase III study of the Italian Lung Cancer Project. J Clin Oncol. 1999; 17:3522-3530.
17. van Zandwijk N, Smit EF, Kramer GWP, et al. Gemcitabine and cisplatin as induction regimen for patients with biopsyproven Stage IIIA N2 non-small-cell lung cancer: a Phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol. 2000;18:2658-2664.
18. Rinaldi M, Crinò L, Scagliotti GV, et al. A three-week schedule of gemcitabicine-cisplatin in advanced non-small cell-lung cancer with two different cisplatin dose levels: a Phase II randomized trial. Ann Oncol. 2000;10:1295-1300.
19. National Cancer Institute. Common toxicity criteria: National Institutes of Health, Cancer Therapy Evaluation Program, Division of Cancer Treatment. Bethesda: National Cancer Institute, 1993.
20. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
21. Van Kooten M, Rosenberg M, Morero J, Chacòn R, Orlando M. Phase II study of gemcitabine plus cisplatin as induction regimen for patients with Stage IIIA-IIIB non-small cell lung cancer. Proc Am Soc Clin Oncol. 1999;18:A526.
22. Yang CH, Tsai CM, Wang LS, et al. Gemcitabine and cisplatin in a multimodality treatment for locally advanced non small cell lung cancer. Br J Cancer. 2002;86:190-195.
23. Crinò L, Betti M, Gregorc V, et al. Induction chemotherapy with gemcitabine and cisplatin in locally advanced Stage III non small cell lung cancer. A Phase II study. Proc Am Soc Clin Oncol. 1999;18:A488.
24. Migliorino MR, De Marinis F, Nelli F, et al. A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for Stage III non-small cell lung cancer. Lung Cancer. 2002;35:319-327.
25. Pisters KMW, Ginsberg RJ, Putnam JB, et al. Induction paclitaxel and carboplatin (PC) in early stage non-small cell lung cancer (NSCLC): early results of a completed Phase II trial. Proc Am Soc Clin Oncol. 1999;18:A467.
26. Eberhardt W, Wilke H, Stamatis G, et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: mature results of a Phase II trial. J Clin Oncol. 1998;16:662-634.
27. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/ etoposide plus chest radiotherapy followed by surgery for Stage IIIAN2 and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group Phase II study 8805. J Clin Oncol. 1995;13:1880-1892.
28. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000;18:2981-2989.